Literature DB >> 29943267

The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients.

H Shuang1, J Feng1, C Caineng1, J Qifeng1, J Tin1, C Yuanyuan2, C Xiaozhong3.   

Abstract

BACKGROUND: To explore the efficacy and patterns of treatment failure of radical radiotherapy in newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients.
METHODS: We included 39 newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients who received radical radiotherapy and chemotherapy in Zhejiang Cancer Hospital. Treatment and prognosis information were collected. The Kaplan-Meier methods and Cox proportional hazards models were used to calculate survival rates and analyze prognostic factors.
RESULTS: After a median follow-up time of 38 months, the 1-, 3-, and 5-year overall survival rates were 97, 70, and 57.9%, while the 1-, 3-, and 5-year progression-free survival rates were 87, 59, and 50.9%, respectively. Age, numbers of metastases lesions, cycles, and schemes of chemotherapy were independent prognostic factors of the overall survival. Patients with no more than three metastasis lesions had a higher survival rate than those with ≥ 3 metastatic lesions (P = 0.023). More than four cycles chemotherapy provide a higher survival rate than less than four cycles. Chemotherapy including docetaxel had a significantly survival advantages (P = 0.041).
CONCLUSION: Radical radiotherapy is important for newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients, which can still achieve long-term survival after chemo-radiotherapy.

Entities:  

Keywords:  Nasopharyngeal neoplasms; Oligo-metastases; Prognosis; Radiotherapy

Mesh:

Year:  2018        PMID: 29943267     DOI: 10.1007/s12094-018-1911-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  7 in total

1.  Synchronous Metastatic Nasopharyngeal Carcinoma: Characteristics and Survival of Patients Adding Definitive Nasopharyngeal-Neck Radiotherapy to Systematic Chemotherapy.

Authors:  Wenjun Liao; Jinlan He; Qiheng Gou; Baofeng Duan; Lei Liu; Ping Ai; Yanchu Li; Kexing Ren; Nianyong Chen
Journal:  Cancer Manag Res       Date:  2020-10-15       Impact factor: 3.989

2.  An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.

Authors:  Sik-Kwan Chan; Brian O'Sullivan; Shao Hui Huang; Tin-Ching Chau; Ka-On Lam; Sum-Yin Chan; Chi-Chung Tong; Varut Vardhanabhuti; Dora Lai-Wan Kwong; Chor-Yi Ng; To-Wai Leung; Mai-Yee Luk; Anne Wing-Mui Lee; Horace Cheuk-Wai Choi; Victor Ho-Fun Lee
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

3.  Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.

Authors:  Xinfang Yu; Ruike Wang; Yangnan Zhang; Li Zhou; Wei Wang; Haidan Liu; Wei Li
Journal:  Oncogene       Date:  2019-08-21       Impact factor: 9.867

4.  Characteristic And Novel Therapeutic Strategies Of Nasopharyngeal Carcinoma With Synchronous Metastasis.

Authors:  Wenjun Liao; Maolang Tian; Nianyong Chen
Journal:  Cancer Manag Res       Date:  2019-09-16       Impact factor: 3.989

5.  Investigation of the Definition of De Novo Oligometastatic Nasopharyngeal Carcinoma: A Retrospective Study.

Authors:  Hongmei Wang; Fang He; Xuejun Wang; Haoyun Tao; Zhihao Huang; Yawei Yuan; Weijun Zhang
Journal:  J Oncol       Date:  2021-09-15       Impact factor: 4.375

6.  Prognostic factors in metastatic nasopharyngeal carcinoma.

Authors:  Nabil Toumi; Sana Ennouri; Ilhem Charfeddine; Jamel Daoud; Afef Khanfir
Journal:  Braz J Otorhinolaryngol       Date:  2020-07-04

7.  MiR-154-5p Suppresses Cell Invasion and Migration Through Inhibiting KIF14 in Nasopharyngeal Carcinoma.

Authors:  Jie Chen; Chengxian Ma; Yufeng Zhang; Shuai Pei; Mingyu Du; Yujie Zhang; Luxi Qian; Jianlin Wang; Li Yin; Xia He
Journal:  Onco Targets Ther       Date:  2020-03-13       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.